SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001664710-22-000019
Filing Date
2022-05-05
Accepted
2022-05-05 08:18:17
Documents
51
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q kros-20220331.htm   iXBRL 10-Q 1064555
2 EX-31.1 exhibit311q12022.htm EX-31.1 17332
3 EX-31.2 exhibit312q12022.htm EX-31.2 17213
4 EX-32.1 exhibit321q12022.htm EX-32.1 9945
  Complete submission text file 0001664710-22-000019.txt   3655565

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20220331.xsd EX-101.SCH 22927
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT kros-20220331_cal.xml EX-101.CAL 39873
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT kros-20220331_def.xml EX-101.DEF 77897
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20220331_lab.xml EX-101.LAB 317939
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20220331_pre.xml EX-101.PRE 194068
45 EXTRACTED XBRL INSTANCE DOCUMENT kros-20220331_htm.xml XML 370363
Mailing Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421
Business Address 99 HAYDEN AVENUE, SUITE 120 (BLD E) LEDGEMONT TECHNOLOGY CENTER LEXINGTON MA 02421 617-513-8774
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39264 | Film No.: 22894207
SIC: 2834 Pharmaceutical Preparations